本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

NovoCure Limited

16.51
+0.93005.97%
盘前16.510.00000.00%04:26 EDT
成交量:87.22万
成交额:1,431.00万
市值:18.15亿
市盈率:-10.56
高:16.60
开:16.00
低:16.00
收:15.58
数据加载中...
2025/01/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/17

重要事件披露

Form 8-K/A - Current report: [Amend]
2024/12/02

重要事件披露

Form 8-K - Current report
2024/10/30

重要事件披露

Form 8-K - Current report
2024/10/30

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/15

重要事件披露

Form 8-K - Current report
2024/09/03

重要事件披露

Form 8-K - Current report
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/25

重要事件披露

Form 8-K - Current report
2024/07/10

SEC问询函

Form CORRESP - Correspondence
2024/07/10

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]